7:04 PM
 | 
Jan 06, 2019
 |  BC Extra  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis.

The deal comes less than a month after Gilead...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >